Sepracor said that it is offering to repurchase all of the outstanding Notes at a price of $1,000.00 per $1,000.00 principal amount of Notes, plus any accrued and unpaid liquidated damages on the Notes to, but excluding, the Expiration Date. The tender offer has been commenced by Sepracor pursuant to the terms of that certain Indenture, dated as of September 22, 2004 (as subsequently supplemented, the "Indenture"), between Sepracor and The Bank of New York Mellon (as successor to JPMorgan Chase Bank), as trustee (the "Trustee"), governing the Notes, as a result of the occurrence of a "Designated Event" (as defined in the Indenture). The Designated Event occurred on October 15, following the expiration of the initial offering period of a tender offer to acquire all of the outstanding common stock of Sepracor commenced by Aptiom, Inc., a Delaware corporation and an indirect subsidiary of Dainippon Sumitomo Pharma Co., a joint stock corporation incorporated under the laws of Japan ("DSP").

Sepracor is a specialty pharmaceutical company.

((Comments on this story may be sent to health@closeupmedia.com))

On 20/10/09, Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. (NASDAQ:SEPR) announce the successful completion of DSP's acquisition of Sepracor for US$23.00 per share in cash.

On 20/10/09, Sinobiopharma, Inc. (OCT:SNBP) is pleased to present the following highlights from the unaudited financial results for the first quarter ended August 31, 2009.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

CONTACT: M. Davila, Editor, BioMedReports.Com e-mail: support@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

As a result of the merger, each outstanding share of Sepracor common stock not validly tendered and accepted for payment in the tender offer was, subject to the exercise of appraisal rights under Delaware law, converted into the right to receive the same $23 in cash per share, without interest and subject to applicable withholding of taxes, that was paid in the tender offer.

Computershare Trust Company is the paying agent for the merger. As a result of the merger, trading of Sepracor common stock on the Nasdaq Global Select Market has ceased and Sepracor no longer has reporting obligations under the Securities Exchange Act of 1934.

Nomura Securities and Thomas Weisel Partners acted as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison acted as legal advisor to DSP.

JP Morgan Securities and Jefferies & Company acted as financial advisors and Willkie Farr & Gallagher and Wilmer Cutler Pickering Hale and Dorr acted as legal advisors to Sepracor.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Holders with questions regarding the tender offer may contact The Bank of New York Mellon, in its capacity as depositary for the tender offer (the "Depositary"), at (212) 815-8394 or Sepracor at (508) 787-4289. Requests for additional copies of the Offer to Purchase, the Letter of Transmittal or other related documents should be directed to the Depositary at the number listed above.

None of Sepracor, DSP, or any of their respective affiliates, officers, or directors or the Trustee or the Depositary make any recommendation as to whether or not Holders should tender their Notes pursuant to the tender offer. Holders must decide how many Notes they will tender, if any.

This press release is for informational purposes only and does not constitute an offer to purchase nor a solicitation for acceptance of the tender offer described above. The tender offer is being made solely pursuant to the Offer to Purchase, Letter of Transmittal and related materials that the Depositary will distribute to Holders. Holders should read carefully the Offer to Purchase, Letter of Transmittal and related materials because they contain important information regarding the tender offer.

About Sepracor

Sepracor is a fully integrated specialty pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs. Sepracor's drug development, corporate development, and licensing efforts have yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Sepracor's currently marketed products in the U.S. include LUNESTA(R) brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol tartrate Inhalation Aerosol, BROVANA(R) brand arformoterol tartrate Inhalation Solution, OMNARIS(R) brand ciclesonide Nasal Spray and ALVESCO(R) brand ciclesonide HFA Inhalation Aerosol. Sepracor's wholly owned subsidiary, Sepracor Pharmaceuticals, Inc., markets several additional products in Canada that are focused in the cardiovascular, central nervous system, pain and infectious disease therapeutic areas. Sepracor has approximately 2,100 employees worldwide. Additional information about Sepracor is available through its corporate web site at http://www.sepracor.com.

Forward-Looking Statements

This announcement contains forward-looking statements that involve significant risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements regarding the expected timing of the Expiration Date, and any statements of assumptions underlying any of the foregoing. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Sepracor does not undertake any obligation to update or revise any forward-looking statements as a result of new information, future developments or otherwise.

Lunesta, Xopenex, Xopenex HFA and Brovana are registered trademarks of Sepracor Inc. Omnaris and Alvesco are registered trademarks of Nycomed GmbH.

For a copy of this release or any recent release, visit Sepracor's web site at www.sepracor.com.

SOURCE: Sepracor Inc.

Company Name: Sepracor Inc. 
Representative: Adrian Adams, President and Chief Executive Officer 
Contact: Jonae R. Barnes, 
Sr. Vice President, Investor Relations and Corporate Communications 
Phone: 508-481-6700